This is a combination of ceftriaxone (a broad-spectrum cephalosporin antibiotic) and sulbactam (a beta-lactamase inhibitor that helps overcome bacterial resistance), used together to treat serious or life-threatening bacterial infections. It is a prescription-only, hospital-administered injectable medicine.

• Therapeutic Class: Combination antibacterial (antibiotic plus beta-lactamase inhibitor).

• Pharmacological Class: Third-generation cephalosporin (ceftriaxone) plus beta-lactamase inhibitor (sulbactam).

• Drug Family: Cephalosporin/beta-lactamase inhibitor combinations.

• ATC Classification: J01DD62 (Ceftriaxone, combinations).

Approved/established use: Serious or life-threatening bacterial infections caused by ceftriaxone-sensitive, beta-lactamase-producing pathogens, including sepsis, meningitis, bone/joint infections, skin/soft tissue infections, respiratory tract infections, urinary tract infections, and intra-abdominal infections.

Commonly used for: Hospitalised patients with moderate to severe infections, particularly where resistant, beta-lactamase-producing bacteria are suspected or confirmed.

Off-label use (only under medical guidance): Sometimes used for other infection types based on culture and sensitivity results, under infectious disease/physician guidance.

• Injection (intravenous/intramuscular, powder for reconstitution): commonly available in a 2:1 ceftriaxone-to-sulbactam ratio, such as 1 g ceftriaxone/0.5 g sulbactam and 2 g ceftriaxone/1 g sulbactam vials.

Ceftriaxone kills bacteria by binding to proteins involved in building the bacterial cell wall, preventing the wall from forming properly and causing the bacteria to die. Some bacteria produce an enzyme called beta-lactamase that can break down and inactivate ceftriaxone before it can work. Sulbactam blocks this enzyme, protecting ceftriaxone from being broken down and restoring its effectiveness against these resistant bacteria.

Standard dose (adults and children 12 years and older): 1 g (ceftriaxone) plus 0.5 g (sulbactam) to 2 g plus 1 g, given once daily or in two divided doses; the total daily ceftriaxone dose should not exceed 4 g.

Condition-wise dose (children 1 month to 12 years): 50-75 mg/kg/day (ceftriaxone component), given once daily or in two divided doses, based on the specific infection and severity.

Route: Intravenous infusion or intramuscular injection, administered by a healthcare professional in a hospital or clinic setting.

Missed dose: Not applicable in typical outpatient sense, as this is a healthcare-provider-administered medicine on a defined schedule; any gap in dosing is managed by the treating team.

Overdose: May increase the risk of known side effects; requires medical attention and supportive care.

• Common: Pain and swelling at the injection site, mild skin rash, diarrhoea, nausea, and vomiting.

• Serious: Severe allergic reactions (particularly in those with penicillin/cephalosporin allergy), Clostridioides difficile-associated diarrhoea, and, rarely, blood disorders or liver enzyme changes.

• Emergency symptoms: Signs of a severe allergic reaction (swelling of the face/throat, difficulty breathing, widespread rash), severe or bloody diarrhoea, or black/tarry stools.

• Recovery advice: Completing the full prescribed course, even if symptoms improve early, is important to reduce the risk of treatment failure and antibiotic resistance.

• Pregnancy: Used only if clearly needed, under medical guidance.

• Breastfeeding: Generally considered compatible with medical guidance; both components pass into breast milk in small amounts.

• Liver disease: Used with caution; no major dose adjustment typically required unless combined with significant kidney impairment.

• Kidney disease: Used with caution; dose adjustment may be needed in significant impairment.

• Elderly: Used with routine monitoring; no specific major dose adjustment based on age alone.

• Children: Approved for children 1 month and older, with weight-based dosing.

• Calcium-containing intravenous products: ceftriaxone should not be mixed or co-administered with calcium-containing solutions, particularly in neonates, due to a risk of serious precipitation.

• Other antibiotics: not typically mixed in the same infusion; ceftriaxone should not be mixed with other antibiotics or diluents containing calcium.

• Anticoagulants: caution advised, as cephalosporins can occasionally affect blood clotting.

• Probenecid: does not significantly affect ceftriaxone elimination in the way it does some other antibiotics, but any combination should still be reviewed by the treating doctor.

• Signs of allergic reaction during and after each dose, particularly the first.

• Kidney and liver function tests periodically during longer courses.

• Complete blood counts with prolonged therapy.

• Clinical response monitoring (fever, infection markers) to assess treatment effectiveness.

Cefoperazone/sulbactam, ceftazidime/sulbactam, piperacillin/tazobactam (other beta-lactam/beta-lactamase inhibitor combinations, chosen based on the suspected or confirmed pathogen).

This is itself a fixed combination; sometimes used alongside other antibiotics for broader coverage in severe or polymicrobial infections, guided by culture and sensitivity results.

• Severe Bacterial Infection Treatments

• Cephalosporin Antibiotics

• Beta-Lactamase Inhibitor Combinations

1. World Sepsis Day

2. Antibiotics Vs Probiotics - On Your Gut

3. Buy Natural Antibiotics - Ancient Secrets For Healthy Living

• https://www.nafdac.gov.ng/wp-content/uploads/Files/SMPC/Ceftriaxone-and-sulbactam.pdf-injection

• https://pmc.ncbi.nlm.nih.gov/articles/PMC6767967/

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.